Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel treatment solutions for a variety of diseases, particularly those with high unmet medical needs. The company's research emphasizes innovative approaches within the realms of rare metabolic and inflammatory conditions. Applied Therapeutics leverages advanced scientific insights to target biochemical pathways implicated in disease progression, aiming to deliver transformative therapies to patients. Their product pipeline includes potential treatments for conditions such as Galactosemia and Sorbitol dehydrogenase deficiency, addressing significant therapeutic gaps in these areas. Headquartered in New York City, Applied Therapeutics plays a crucial role in the biotechnology sector by potentially expanding the range of available therapies for orphan diseases. Through its commitment to cutting-edge research and development, the company contributes to the dynamic landscape of biopharmaceutical solutions, enhancing the prospects of improved health outcomes for patients affected by these challenging diseases.